Dr Kurt Miller from Berlin, Germany, reviews the novel non-androgen receptor (AR) therapeutic targets in CRPC. Outlining the different mechanisms by which CRPC develops, Dr Miller explains why non-AR targets are valid, and reviews the treatments available and in the pipeline.
This video is sponsored by an educational grant from Janssen Asia Pacific, a pharmaceutical company of Johnson & Johnson